<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixty-four patients with proven <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> who had been maintained on sulphasalazine as their sole form of treatment for a minimum period of one year were entered into a controlled trial of sulphasalazine versus dummy tablets for a period of six months </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients admitted were not only symptom-free but also showed no evidence of <z:mp ids='MP_0001845'>inflammation</z:mp> on sigmoidoscopy and rectal biopsy </plain></SENT>
<SENT sid="2" pm="."><plain>A patient was judged to have relapsed when there was a recurrence of colitic symptoms accompanied by sigmoidoscopic and histological evidence of <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The patients who received dummy tablets had more than four times the relapse rate of those receiving sulphasalazine </plain></SENT>
<SENT sid="4" pm="."><plain>The results were similar in patients who had been on maintenance treatment with sulphasalazine for less than three years before entry into the trial and in those who had been on this treatment for more than three years </plain></SENT>
<SENT sid="5" pm="."><plain>It is concluded that maintenance treatment of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> with sulphasalazine should be continued indefinitely unless contraindicated by side effects </plain></SENT>
</text></document>